Android app Apple app link

Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

By Yahoo! Finance   |   3 weeks ago
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

Regeneron Pharmaceuticals announced FDA's Priority Review for EYLEA HD Injection 8 mg for treating macular edema and broadening dosing schedule. The target action date is August 19, 2025, supported by data from the Phase 3 QUASAR trial.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.